Amgen Inc. AMGN.TO
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About AMGN.TO
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Amgen Inc. is a U.S.-based biotechnology company focused on the discovery, development, manufacturing, and commercialization of human therapeutics. The company operates primarily within the biotechnology and pharmaceutical industries, with a portfolio spanning oncology, inflammation, cardiovascular disease, bone health, nephrology, and rare diseases. Its major revenue drivers include biologic medicines and biosimilars, with products such as Enbrel, Prolia, XGEVA, Otezla, Repatha, and TEPEZZA contributing significantly to commercial performance according to recent SEC filings and investor materials.
Amgen was founded in 1980 in California and emerged as one of the earliest large-scale biotechnology companies to successfully commercialize recombinant biologic therapies. Over time, the company expanded from erythropoiesis-stimulating agents and supportive cancer care into broader therapeutic categories through internal research, licensing, and acquisitions. Amgen’s strategic positioning is supported by advanced biologics manufacturing capabilities, extensive intellectual property assets, and a growing biosimilars platform designed to compete in markets facing biologic patent expirations.
Business Operations
Amgen generates revenue primarily through sales of innovative therapeutics and biosimilar products across global healthcare markets. The company organizes operations around key therapeutic franchises rather than publicly reporting numerous independent business divisions. Core commercial areas include oncology, inflammation, bone health, cardiovascular disease, nephrology, and rare disease therapeutics. Its biosimilars portfolio has become an increasingly important business line, targeting reference biologics across oncology and immunology indications. Revenue is derived from direct product sales, licensing arrangements, and collaborations with healthcare distributors, hospitals, pharmacies, and government healthcare systems.
The company maintains substantial domestic operations in the United States while operating internationally across Europe, Asia-Pacific, Latin America, and other regions. Amgen controls large-scale biologics manufacturing infrastructure and research capabilities that support both proprietary medicines and biosimilar development. Key subsidiaries and acquired businesses include Horizon Therapeutics, acquired in 2023 to strengthen Amgen’s rare disease portfolio. The company has also maintained strategic collaborations with biotechnology firms, academic institutions, and commercial partners to advance drug development and market expansion.
Strategic Position & Investments
Amgen’s strategic direction centers on expanding its innovative medicines portfolio, strengthening rare disease capabilities, increasing biosimilars penetration, and leveraging advanced biologics manufacturing and data-driven drug development. The acquisition of Horizon Therapeutics represented one of the company’s largest strategic investments, adding products such as TEPEZZA, KRYSTEXXA, and UPLIZNA to its portfolio. Amgen has also invested heavily in obesity, inflammation, oncology, and cardiometabolic research pipelines, including next-generation biologics and targeted therapeutics.
The company continues to allocate capital toward research and development, manufacturing expansion, and selective acquisitions intended to diversify long-term revenue sources beyond mature legacy products. Amgen has shown increasing involvement in emerging therapeutic areas including obesity management and precision medicine. Public disclosures in SEC filings and earnings materials indicate that management views biosimilars and rare diseases as long-term growth platforms alongside established innovative biologic franchises.
Geographic Footprint
Amgen is headquartered in Thousand Oaks, California, and maintains operations across major global pharmaceutical markets. The company has a significant presence in North America, Europe, Asia-Pacific, and Latin America, supported by regional commercial offices, manufacturing facilities, and distribution networks. International revenue contributes a substantial portion of total company sales, with Europe representing one of the largest markets outside the United States.
The company’s global operational footprint includes manufacturing and research facilities in the United States, Ireland, Puerto Rico, the Netherlands, and Singapore, among other locations identified in public filings. Amgen’s medicines are distributed in more than 100 countries through direct operations and strategic partnerships. Its international expansion strategy has emphasized biologics manufacturing scale, regulatory capabilities, and broader penetration of biosimilars into global healthcare systems.
Leadership & Governance
Amgen’s leadership structure combines biotechnology research expertise with large-scale pharmaceutical commercialization and manufacturing experience. The company’s governance framework is overseen by a board of directors and executive leadership team responsible for long-term strategy, capital allocation, scientific innovation, and regulatory compliance. Public company disclosures emphasize a strategic focus on innovation, operational efficiency, and sustainable long-term growth through both internal research and external business development.
Key executives include:
- Robert A. Bradway – Chairman and Chief Executive Officer
- Peter H. Griffith – Executive Vice President and Chief Financial Officer
- David M. Reese – Executive Vice President and Chief Technology Officer
- Murdo Gordon – Executive Vice President, Global Commercial Operations
- Jay Bradner – Executive Vice President, Research and Development
- Roger M. Perlmutter – Former Executive Vice President, Research and Development and influential scientific leader in Amgen’s historical development
Amgen’s leadership philosophy, as reflected in shareholder communications and investor presentations, emphasizes science-driven innovation, disciplined capital deployment, manufacturing reliability, and long-term therapeutic impact in serious diseases.